- Home
- KMT vs AKRO Comparison
KMT vs AKRO Comparison
Compare KMT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KMT | AKRO |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | KMT | AKRO |
|---|---|---|
| Price | $28.59 | $54.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $24.60 | ★ $73.56 |
| AVG Volume (30 Days) | 817.6K | ★ 2.4M |
| Earning Date | 02-04-2026 | 11-07-2025 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,982,871,000.00 | N/A |
| Revenue This Year | $7.69 | N/A |
| Revenue Next Year | $3.82 | N/A |
| P/E Ratio | $23.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.30 | $21.34 |
| 52 Week High | $29.89 | $58.40 |
Technical Indicators
Market Signals| Indicator | KMT | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 61.66 | 68.63 |
| Support Level | $28.39 | $54.30 |
| Resistance Level | $29.89 | $54.70 |
| Average True Range (ATR) | 0.59 | 0.17 |
| MACD | -0.14 | -0.10 |
| Stochastic Oscillator | 50.37 | 71.07 |
Price Performance
Historical ComparisonAbout KMT Kennametal Inc.
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.